Literature DB >> 30267154

What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?

Diomidis Botsikas1, Ilias Bagetakos2, Marlise Picarra2,3, Ana Carolina Da Cunha Afonso Barisits2, Sana Boudabbous2, Xavier Montet2, Giang Thanh Lam4, Ismini Mainta5, Anastasia Kalovidouri2, Minerva Becker2.   

Abstract

PURPOSE: To compare the diagnostic performance of 18-FDG-PET/MR and PET/CT for the N- and M- staging of breast cancer. METHODS AND MATERIALS: Two independent readers blinded to clinical/follow-up data reviewed PET/MR and PET/CT examinations performed for initial or recurrent breast cancer staging in 80 consecutive patients (mean age = 48 ± 12.9 years). The diagnostic confidence for lesions in the contralateral breast, axillary/internal mammary nodes, bones and other distant sites were recorded. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) were calculated. The standard of reference included pathology and/or follow-up > 12 months.
RESULTS: Nine of 80 patients had bone metastases; 13/80 had other distant metastases, 44/80 had axillary, 9/80 had internal mammary and 3/80 had contralateral breast tumours. Inter-reader agreement for lesions was excellent (weighted kappa = 0.833 for PET/CT and 0.823 for PET/MR) with similar reader confidence for the two tests (ICC = 0.875). In the patient-per-patient analysis, sensitivity and specificity of PET/MRI and PET/CT were similar (p > 0.05). In the lesion-per-lesion analysis, the sensitivity of PET/MR and PET/CT for bone metastases, other metastases, axillary and internal mammary nodes, contralateral tumours and all lesions together was 0.924 and 0.6923 (p = 0.0034), 0.923 and 0.923 (p = 1), 0.854 and 0.812 (p = 0.157), 0.9 and 0.9 (p = 1), 1 and 0.25 (p = 0.083), and 0.89 and 0.77 (p = 0.0013) respectively. The corresponding specificity was 0.953 and 1 (p = 0.0081), 1 and 1 (p = 1), 0.893 and 0.92 (p = 0.257), 1 and 1 (p = 1), 0.987 and 0.99 (p = 1) and 0.96 and 0.98 (p = 0.0075) respectively.
CONCLUSIONS: Reader confidence, inter-reader agreement and diagnostic performance per patient were similar with PET/MR and PET/CT. However, for all lesions together, PET/MR had a superior sensitivity and lower specificity in the lesion-per-lesion analysis. KEY POINTS: • N and M breast cancer staging performance of PET/MR and PET/CT is similar per patient. • In a lesion-per-lesion analysis PET/MR is more sensitive than PET/CT especially for bone metastasis. • Readers' diagnostic confidence is similar for both tests.

Entities:  

Keywords:  Breast neoplasms; Magnetic resonance imaging; Neoplasm staging; Positron emission tomography computed tomography

Mesh:

Substances:

Year:  2018        PMID: 30267154     DOI: 10.1007/s00330-018-5720-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.

Authors:  Lino M Sawicki; Johannes Grueneisen; Benedikt M Schaarschmidt; Christian Buchbender; James Nagarajah; Lale Umutlu; Gerald Antoch; Sonja Kinner
Journal:  Eur J Radiol       Date:  2015-12-19       Impact factor: 3.528

2.  Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study.

Authors:  Pascal A T Baltzer; Matthias Dietzel; Hartmut P Burmeister; Ramy Zoubi; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser
Journal:  AJR Am J Roentgenol       Date:  2011-05       Impact factor: 3.959

3.  Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.

Authors:  Leonardo Pace; Emanuele Nicolai; Angelo Luongo; Marco Aiello; Onofrio A Catalano; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Radiol       Date:  2013-11-23       Impact factor: 3.528

Review 4.  MRI for solitary pulmonary nodule and mass assessment: Current state of the art.

Authors:  Yoshiharu Ohno; Hans-Ulrich Kauczor; Hiroto Hatabu; Joon Beom Seo; Edwin J R van Beek
Journal:  J Magn Reson Imaging       Date:  2018-03-23       Impact factor: 4.813

5.  Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.

Authors:  Onofrio Antonio Catalano; Dania Daye; Alberto Signore; Carlo Iannace; Mark Vangel; Angelo Luongo; Marco Catalano; Mazzeo Filomena; Luigi Mansi; Andrea Soricelli; Marco Salvatore; Niccolo Fuin; Ciprian Catana; Umar Mahmood; Bruce Robert Rosen
Journal:  Int J Oncol       Date:  2017-05-19       Impact factor: 5.650

6.  Application of breast MRI for prediction of lymph node metastases - systematic approach using 17 individual descriptors and a dedicated decision tree.

Authors:  Matthias Dietzel; Pascal A T Baltzer; Tibor Vag; Tobias Gröschel; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser
Journal:  Acta Radiol       Date:  2010-10       Impact factor: 1.990

Review 7.  PET/MR in Breast Cancer.

Authors:  Claire Tabouret-Viaud; Diomidis Botsikas; Bénédicte M A Delattre; Ismini Mainta; Gaël Amzalag; Olivier Rager; Vincent Vinh-Hung; Raymond Miralbell; Osman Ratib
Journal:  Semin Nucl Med       Date:  2015-07       Impact factor: 4.446

Review 8.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

9.  Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.

Authors:  Amy N Melsaether; Roy A Raad; Akshat C Pujara; Fabio D Ponzo; Kristine M Pysarenko; Komal Jhaveri; James S Babb; Eric E Sigmund; Sungheon G Kim; Linda A Moy
Journal:  Radiology       Date:  2016-03-29       Impact factor: 11.105

10.  Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.

Authors:  Thiemo J A van Nijnatten; B Goorts; S Vöö; M de Boer; L F S Kooreman; E M Heuts; J E Wildberger; F M Mottaghy; M B I Lobbes; M L Smidt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-14       Impact factor: 9.236

View more
  14 in total

Review 1.  Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.

Authors:  Wei Wang; Pengfei Qiu; Jianbin Li
Journal:  Breast Cancer       Date:  2022-06-24       Impact factor: 3.307

Review 2.  PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer.

Authors:  Elizabeth A Sadowski; Ali Pirasteh; Alan B McMillan; Kathryn J Fowler; Joanna E Kusmirek
Journal:  Abdom Radiol (NY)       Date:  2021-10-23

Review 3.  A review on the added value of whole-body MRI in metastatic lobular breast cancer.

Authors:  Basrull N Bhaludin; Nina Tunariu; Dow-Mu Koh; Christina Messiou; Alicia F Okines; Sophie E McGrath; Alistair E Ring; Marina M Parton; Bhupinder Sharma; Tanja Gagliardi; Steven D Allen; Romney Pope; Stephen R D Johnston; Kate Downey
Journal:  Eur Radiol       Date:  2022-04-06       Impact factor: 7.034

4.  Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.

Authors:  Nils Martin Bruckmann; Julian Kirchner; Janna Morawitz; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Andreas Stang; Gerald Antoch; Lino M Sawicki; Christian Buchbender
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

5.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

6.  Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms.

Authors:  Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Swetlana Mohrmann; Thomas Gauler; Sarah Theurer; Christina Antke; Irene Esposito; Sonja Kinner; Benedikt M Schaarschmidt; Bernd Kowall; Diana Lütke-Brintrup; Andreas Stang; Anton S Becker; Gerald Antoch; Christian Buchbender
Journal:  Eur J Radiol       Date:  2020-04-24       Impact factor: 4.531

7.  Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT.

Authors:  Dong Zheng; Yi Liu; Jiajin Liu; Ke Li; Mu Lin; Holger Schmidt; Baixuan Xu; Jiahe Tian
Journal:  Cancer Imaging       Date:  2020-06-16       Impact factor: 3.909

8.  Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.

Authors:  Nils Martin Bruckmann; Lino M Sawicki; Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Wolfgang Fendler; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Frederic Dietzel; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Bernd Kowall; Andreas Stang; Gerald Antoch; Christian Buchbender
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-24       Impact factor: 9.236

9.  The NILS Study Protocol: A Retrospective Validation Study of an Artificial Neural Network Based Preoperative Decision-Making Tool for Noninvasive Lymph Node Staging in Women with Primary Breast Cancer (ISRCTN14341750).

Authors:  Ida Skarping; Looket Dihge; Pär-Ola Bendahl; Linnea Huss; Julia Ellbrant; Mattias Ohlsson; Lisa Rydén
Journal:  Diagnostics (Basel)       Date:  2022-02-24

10.  Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients.

Authors:  Cornelis Maarten de Mooij; Inés Sunen; Cristina Mitea; Ulrich C Lalji; Sigrid Vanwetswinkel; Marjolein L Smidt; Thiemo J A van Nijnatten
Journal:  Nucl Med Commun       Date:  2020-10       Impact factor: 1.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.